==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Browse result page of THPdb

The total number entries retrieved from this search are 15
IDThPPIDNamePeptide SequenceLengthFunctional ClassificationDiseaseBrandCompanyPhysical AppearanceRoute of AdministartionCategoryTarget
1537Th1116CanakinumabH-GAMMA-1 (VH(1-118) Full view842IIIbImmunologicalILARIS Novartis PharmaceuticalsWhite, preservative-free, lyophilized powderSubcutaneous injectionAnti-Inflammatory Agents and Monoclonal antibodies Interleukin-1 beta
1548Th1117IpilimumabHeavy chain: QVQLVES Full view663IIIcCancerYERVOYBristol-Myers SquibbSterile, preservative-free, clear to slightly opalescent, colorless to pale-yellow solutionN.A.Antineoplastic Agents and Monoclonal antibodies Cytotoxic T-lymphocyte protein 4
1560Th1121Pertuzumablight chain DIQMTQSP Full view664IIIcCancerPerjetaGenentechSterile, clear to slightly opalescent, colorless to pale brown liquidIntravenous infusionMonoclonal antibodies Receptor tyrosine-protein kinase erbB-2
1570Th1123DenosumabHeavy chain EVQLLESG Full view664IIIcOsteologicalXgevaAmgen.Sterile, preservative-free, clear, colorless to pale yellow solutionN.A.Bone Density Conservation Agents and Monoclonal antibodies Tumor necrosis factor ligand superfamily member 11
1571Th1123DenosumabHeavy chain EVQLLESG Full view664IIIcOsteologicalProliaAmgen.Sterile, preservative-free, clear, colorless to pale yellow solutionN.A.Bone Density Conservation Agents and Monoclonal antibodies Tumor necrosis factor ligand superfamily member 11
1583Th1125GolimumabN.A. Full view0IIbImmunologicalSimponi InjectionN.A.Clear to slightly opalescent, colorless to light yellow solutionSubcutaneous injectionAntipsoriatic Agents and Monoclonal antibodies and TNF inhibitor Tumor necrosis factor
1584Th1125GolimumabN.A. Full view0IIbImmunologicalSimponi InjectionN.A.Sterile concentrated solution of the golimumab antibodyIntravenous infusionAntipsoriatic Agents and Monoclonal antibodies and TNF inhibitor Tumor necrosis factor
1609Th1132BelimumabN.A. Full view0IIaImmunologicalBenlystaGlaxoSmithKlineSterile, white to off-white, preservative-free, lyophilized powderIntravenous infusionMonoclonal antibodies Tumor necrosis factor ligand superfamily member 13B
1627Th1138RaxibacumabN.A. Full view0IIaImmunological/InfectiousRAXIBACUMABGSKSterile, liquid formulation in single-dose vialsN.A.Anti-Infective Agents and Monoclonal antibodies Protective antigen
1708Th1170BlinatumomabDIQLTQSPASLAVSLGQRAT Full view504IIIcCancer/GeneticBlincytoAMGENLyophilized Powder for intravenous administrationIntravenousAntineoplastic Agents, Immunosuppressive Agents, Monoclonal antibodies, Antineoplastic and Immunomodulating Agents B-lymphocyte antigen CD19; T-cell surface glycoprotein CD3 delta chain
1828Th1218Anti-thymocyte Globulin (Equine)NA Full view0IIIbImmunological DisordersATGAMNA Solid IntravenousAntibody NA
1829Th1219Anti-thymocyte Globulin (Rabbit)NA Full view0IIIbImmunological DisordersATG-FreseniusGenzyme Inc.Concentrate for solution for infusion. IntravenousAntibody T-cell surface glycoprotein CD1a, Major histocompatibility complex class I-related gene protein, Integrin alpha-L, T-lymphocyte activation antigen CD86, Low affinity immunoglobulin gamma Fc region receptor II-b, T-cell surface glycoprotein CD4, Integrin beta-1, Integrin alpha-V, Integrin beta-3
1837Th1226DinutuximabNA Full view0IIIcCancerunituxinNAsterile, preservative-free, clear/colorless to slightly opalescent solution Intravenous Antibody, Immunosuppresive agent, Antineoplastic agent Ganglioside GD2 (small molecule)
1842Th1230Human Varicella-Zoster Immune GlobulinNA Full view0IIIaInfectious DiseaseVARIZIGNAlyophilized powder for solutionIntramuscularAntibody varicella zoster virus
1843Th1231Ibritumomab tiuxetanHeavy chain: QAYLQQS Full view652IIIcCancerZevalinSpectrum Pharmaceuticals B.V.Colourless SolutionIntravenousAntibody, Immunosuppressive Agents B-lymphocyte antigen CD20, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c